not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.
2
positions filed
in the 673 files tracked
1
legislative file
of 673 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 673 consultation files tracked so far (58,314 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
3 November 2023 PRI response to the public consultation on a PROPOSAL FOR A REGULATION laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) N 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No…
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Confidential | PRI Internal Use Only | Do Not Distribute 3 Novembre 2023 PRI response to the public consultation on a PROPOSAL FOR A DIRECTIVE relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC Deadline: 8 November 2023 – 4000 characters maximum (currently: 3993).
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Siolta Therapeutics next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Siolta Therapeutics’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.
